تقرير
Pazopanib: a novel treatment option for aggressive fibromatosis.
| العنوان: | Pazopanib: a novel treatment option for aggressive fibromatosis. |
|---|---|
| المؤلفون: | Bulut G; Department of Medical Oncology, Ege University Medical School, Tulay Aktas Oncology Hospital, Ege University, Izmir, Turkey., Ozluk A; Department of Internal Medicine, Ege University Medical School, Ege University Medical School Hospital, Ege University, Izmir, Turkey., Erdogan AP; Department of Medical Oncology, Ege University Medical School, Tulay Aktas Oncology Hospital, Ege University, Izmir, Turkey., Uslu R; Department of Medical Oncology, Ege University Medical School, Tulay Aktas Oncology Hospital, Ege University, Izmir, Turkey., Elmas N; Department of Radiology, Ege University Medical School, Ege University Medical School Hospital, Ege University, Izmir, Turkey., Karaca B; Department of Medical Oncology, Ege University Medical School, Tulay Aktas Oncology Hospital, Ege University, Izmir, Turkey. |
| المصدر: | Clinical sarcoma research [Clin Sarcoma Res] 2016 Dec 01; Vol. 6, pp. 22. Date of Electronic Publication: 2016 Dec 01 (Print Publication: 2016). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101577890 Publication Model: eCollection Cited Medium: Print ISSN: 2045-3329 (Print) Linking ISSN: 20453329 NLM ISO Abbreviation: Clin Sarcoma Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central |
| مستخلص: | Background: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. Case Presentation: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. Conclusion: Pazopanib might be an effective treatment option for AF. |
| References: | Clin Cancer Res. 2011 Jun 15;17(12):4082-90. (PMID: 21447727) Lancet. 2012 May 19;379(9829):1879-86. (PMID: 22595799) Invest New Drugs. 2014 Apr;32(2):369-76. (PMID: 24425345) Ann Oncol. 2011 Feb;22(2):452-7. (PMID: 20622000) Clin Sarcoma Res. 2013 Nov 26;3(1):13. (PMID: 24279994) Diagn Mol Pathol. 1997 Apr;6(2):98-101. (PMID: 9098648) Cancer. 2004 Feb 1;100(3):612-20. (PMID: 14745880) Radiographics. 2016 May-Jun;36(3):767-82. (PMID: 27163593) Ann Oncol. 2012 Mar;23(3):562-9. (PMID: 21859899) J Clin Oncol. 2006 Mar 1;24(7):1195-203. (PMID: 16505440) Clin Cancer Res. 2007 Sep 1;13(17):5034-40. (PMID: 17785554) Expert Rev Anticancer Ther. 2013 Aug;13(8):975-82. (PMID: 23944712) |
| فهرسة مساهمة: | Keywords: Aggressive fibromatosis; Desmoid tumor; Oral tyrosine kinase inhibitor; Pazopanib |
| تواريخ الأحداث: | Date Created: 20161214 Latest Revision: 20200929 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5131445 |
| DOI: | 10.1186/s13569-016-0061-3 |
| PMID: | 27957320 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-3329 |
|---|---|
| DOI: | 10.1186/s13569-016-0061-3 |